Welcome!

News Feed Item

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Lower Limb Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lower Limb Muscle Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lower Limb Muscle Spasticity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Lower Limb Muscle Spasticity 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials by E7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials in E7 Countries by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20

Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Lower Limb Muscle Spasticity Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28
Clinical Trial Overview of Top Companies 28
Merz Pharma GmbH & Co. KgaA 28
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 28
Ipsen S.A. 29
Clinical Trial Overview of Ipsen S.A. 29
Allergan, Inc. 30
Clinical Trial Overview of Allergan, Inc. 30
GlaxoSmithKline plc 31
Clinical Trial Overview of GlaxoSmithKline plc 31
Clinical Trial Overview of Top Institutes / Government 32
The University of Tokushima 32
Clinical Trial Overview of The University of Tokushima 32

Tehran University of Medical Sciences 33
Clinical Trial Overview of Tehran University of Medical Sciences 33
Danish Pain Research Center 34
Clinical Trial Overview of Danish Pain Research Center 34
Assistance Publique Hopitaux De Marseille 35
Clinical Trial Overview of Assistance Publique Hopitaux De Marseille 35
Five Key Clinical Profiles 36
Appendix 112
Abbreviations 112
Definitions 112
Research Methodology 113
Secondary Research 113
About GlobalData 114
Contact Us 114
Disclaimer 114
Source 114

List of Tables

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region, 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 12

Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 13
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23

Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 28
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014* 29
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 30
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 31
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Tokushima, 2014* 32
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 33
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Danish Pain Research Center, 2014* 34
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique Hopitaux De Marseille, 2014* 35

List of Figures

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 12
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17

Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 113

To order this report: Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
"Codigm is based on the cloud and we are here to explore marketing opportunities in America. Our mission is to make an ecosystem of the SW environment that anyone can understand, learn, teach, and develop the SW on the cloud," explained Sung Tae Ryu, CEO of Codigm, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We're focused on how to get some of the attributes that you would expect from an Amazon, Azure, Google, and doing that on-prem. We believe today that you can actually get those types of things done with certain architectures available in the market today," explained Steve Conner, VP of Sales at Cloudistics, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Telecom Reseller has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, introduced two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a multip...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
"CA has been doing a lot of things in the area of DevOps. Now we have a complete set of tool sets in order to enable customers to go all the way from planning to development to testing down to release into the operations," explained Aruna Ravichandran, Vice President of Global Marketing and Strategy at CA Technologies, in this SYS-CON.tv interview at DevOps Summit at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"The reason Tier 1 companies are coming to us is we're able to narrow the gap where custom applications need to be built. They provide a lot of services, like IBM has Watson, and they provide a lot of hardware but how do you bring it all together? Bringing it all together they have to build custom applications and that's the niche that we are able to help them with," explained Peter Jung, Product Leader at Pulzze Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2,...
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...